Yesterday I made a post about one of the main founders of Brilacidin, Dr. DeGrado, a leader in "de novo" molecular engineering recognized worldwide.
The other name associated with IBD and IPIX is a scientific advisor noted on the website, Dr. Francis Farraye. The website gives a one paragraph summary of his accompllishments and they are prodigious.
Area of Expertise: Managing patients with Ulcerative Colitis and Crohns Disease
Author or co-author of over 450 scientific manuscripts, reviews, and abstracts.
Director of IBD Center at Boston Medical Center
Frequent invited speaker on IBD
Currently co-directs IBD Center at the Mayo Clinic in Jacksonville Fl
Recognized as “Top Doctor” in Gastroenterology by Boston Magazine and U.S. News and World Report since 2010.
So it looks like Brilacidin, especially in terms of IBD, has the highest level of professional backing.
As to Kevetrin, its founder, Dr. Menon, was a recognized giant in the cancer field leading the development for two large selling cancer drugs for Eli Lilly & Co.
Dr. Emil Frei was a very close friend of Dr. Menon and he had great things to say about the potential of K. Dr. Frei was a colleague (not sure who was the head guy but pretty sure it was Freireich) in the finding of a cure for childhood leukemia. Dr. Frei was head of Cancer for Dana-Farber when Menon was working on Kevetrin. Note from wikipedia how they (Dr. Frei and Freireich), all thought cancer had to be treated by multiple paths as evidenced by the following excerpt:
"In 1965, Emil Freireich, Emil Frei, and James F. Holland hypothesized that cancer could best be treated by combinations of drugs, each with a different mechanism of action. Cancer cells could conceivably mutate to become resistant to a single agent, but by using different drugs concurrently it would be more difficult for the tumor to develop ...' and how Kevetrin turned into being such a central hub for working as a complementary drug. Either Frei or Menon made the statement that if K was a kitchen component, it would be salt or sugar as it can combine with nearly anything.
That is why many of us long timers are here, for Menon and Frei thought K may be useful in helping up to 50% of the various types of cancers thru either a stand- alone treatment or as a complementary drug to other more toxic cancer treatments.
That dream is still alive for many of us, especially with a pill form for Kevetrin being so close (50% of toxological tests already finished) and simply awaiting the funds to finance the final steps to bring it into being.
Nothing positive to date, but the odds are sure bolstered by the solid scientific background by those who founded our drugs or gave ideas and insight as to how they should/could be improved.
Like our chances for success.
The other name associated with IBD and IPIX is a scientific advisor noted on the website, Dr. Francis Farraye. The website gives a one paragraph summary of his accompllishments and they are prodigious.
Area of Expertise: Managing patients with Ulcerative Colitis and Crohns Disease
Author or co-author of over 450 scientific manuscripts, reviews, and abstracts.
Director of IBD Center at Boston Medical Center
Frequent invited speaker on IBD
Currently co-directs IBD Center at the Mayo Clinic in Jacksonville Fl
Recognized as “Top Doctor” in Gastroenterology by Boston Magazine and U.S. News and World Report since 2010.
So it looks like Brilacidin, especially in terms of IBD, has the highest level of professional backing.
As to Kevetrin, its founder, Dr. Menon, was a recognized giant in the cancer field leading the development for two large selling cancer drugs for Eli Lilly & Co.
Dr. Emil Frei was a very close friend of Dr. Menon and he had great things to say about the potential of K. Dr. Frei was a colleague (not sure who was the head guy but pretty sure it was Freireich) in the finding of a cure for childhood leukemia. Dr. Frei was head of Cancer for Dana-Farber when Menon was working on Kevetrin. Note from wikipedia how they (Dr. Frei and Freireich), all thought cancer had to be treated by multiple paths as evidenced by the following excerpt:
"In 1965, Emil Freireich, Emil Frei, and James F. Holland hypothesized that cancer could best be treated by combinations of drugs, each with a different mechanism of action. Cancer cells could conceivably mutate to become resistant to a single agent, but by using different drugs concurrently it would be more difficult for the tumor to develop ...' and how Kevetrin turned into being such a central hub for working as a complementary drug. Either Frei or Menon made the statement that if K was a kitchen component, it would be salt or sugar as it can combine with nearly anything.
That is why many of us long timers are here, for Menon and Frei thought K may be useful in helping up to 50% of the various types of cancers thru either a stand- alone treatment or as a complementary drug to other more toxic cancer treatments.
That dream is still alive for many of us, especially with a pill form for Kevetrin being so close (50% of toxological tests already finished) and simply awaiting the funds to finance the final steps to bring it into being.
Nothing positive to date, but the odds are sure bolstered by the solid scientific background by those who founded our drugs or gave ideas and insight as to how they should/could be improved.
Like our chances for success.
14
